Dr. Ninaad Lasrado, PhD from the Barouch Lab and team, including Ai-ris Yonekura Collier, MD & Camille Mazurek, show the current XBB.1.5 mRNA boosters substantially enhance peripheral antibody responses but do not robustly increase mucosal antibody responses. Science Translational Medicine | bit.ly/3UqhrMd

Booster doses of an mRNA vaccine for #COVID19 yield only limited mucosal immunity and antibody titers, according to a clinical study that highlights the need for stronger mucosal immunization strategies against #SARSCoV2. Ninaad Lasrado, PhD Barouch Lab BIDMC bit.ly/3YlonLH

Making this open access for everyone to read! pmc.ncbi.nlm.nih.gov/articles/PMC11…

I'm very excited to share our recent paper describing the antigenic relationship of SARS-CoV-2 variants in Nonhuman primates for the first time. Barouch Lab anetzl Ninaad Lasrado, PhD Janine Kimpel Cambridge University Medizinische Uni cell.com/cell-reports/f…

Clinical Trial: Study to Investigate the Efficacy of Abrocitinib in Adult Participants with Severe Fatigue from Long COVID (CLEAR-LC) clinicaltrials.gov/study/NCT06597… Location: Beth Israel Deaconess Medical Center 617-735-4610 Email: [email protected]

Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)

Email [email protected] or call 617-735-4610 to inquire. Additional information can also be found here [clinicaltrials.gov/study/NCT06597…]. (2/2)

#LongCovid has impaired millions of people, with no cure on the horizon. BIDMC_CVVRtrial has launched a trial to test Abrocitinib to alleviate LC symptoms. If you’re around Boston, see if you qualify! 👇Dianna Cowern Michal Tal, PhD Eric Topol Prof. Akiko Iwasaki LongCOVIDCampaign

Boston’s Barouch Lab is testing Abrocitinib, a JAK inhibitor, in a Phase 2 trial to ease Long COVID fatigue, based on earlier findings of JAK-STAT and IL-6 pathway involvement. biorxiv.org/content/10.110… clinicaltrials.gov/study/NCT06597… Join in! This study could make a real difference.

Just launched: Meet Asia’s Forbes 30 Under 30, Class of 2025 on.forbes.com/6013NdMuB #ForbesU30Asia #ForbesUnder30

Introducing the entrepreneurs, innovators and stars who made the 10th edition of the annual 2025 #ForbesU30Asia list on.forbes.com/6013NdMZD

Puttur's Dr Ninaad Lasrado named in Forbes Asia's 30 Under 30 – Health Science List for 2025 - He is currently working as a postdoctoral fellow at Harvard Medical School, Boston, USA. Dr Lasrado completed his PhD in viral immunology from the ... - ift.tt/LE4Xht1

Discovering new worlds, in our cells and outer space. on.forbes.com/6014N51ap #ForbesUnder30 Asia

Selected from thousands of nominations and vetted by our team of reporters and a panel of judges, here are the 300 that made the #ForbesUnder30 Asia 2025 list on.forbes.com/6017NgNjP

Forbes 30 Under 30 Asia 2025 List trib.al/OXdxiUT #ForbesUnder30 Asia

Meet The #ForbesUnder30 Asia Class Of 2025 trib.al/ZskzFMW trib.al/ZskzFMW

A cool PI doing awesome science! Highly recommend for anyone interested in respiratory mucosal immunology👇